

Haematologica
HAEMATOL/2017/167627
Version 1

Minimal residual disease in mantle cell lymphoma: are we ready for a
personalized treatment?

Simone Ferrero and Martin Dreyling

Disclosures: SF: Consultancy: Janssen Advisory Board: Pfizer Speaker's Honoraria: Celgene, Mundipharma, Janssen, Pfizer MD: Scientific Advisory Board: Bayer, Celgene, Gilead, Janssen, Mundipharma, Roche, Sandoz speaker's honoraria: Bayer, Celgene, Gilead, Janssen, Roche (institutional) Research Support: Celgene, Janssen, Mundipharma, Roche

Contributions: Both authors contributed equally